GlaxoSmithKline Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (₹450,569 Mil) to Dec. 2025 (₹419,043 Mil) and
declined
from Dec. 2025 (₹419,043 Mil) to Mar. 2026 (₹386,754 Mil).
GlaxoSmithKline Pharmaceuticals's annual market cap
increased
from Mar. 2024 (₹329,766 Mil) to Mar. 2025 (₹487,949 Mil) but then
declined
from Mar. 2025 (₹487,949 Mil) to Mar. 2026 (₹386,754 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GlaxoSmithKline Pharmaceuticals's Enterprise Value for Today is ₹372,373 Mil.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GlaxoSmithKline Pharmaceuticals Market Cap Related Terms
GlaxoSmithKline Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAXO vs LLY, JNJ, ABBV: Market Cap Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Market Cap falls into.
GlaxoSmithKline Pharmaceuticals Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Market Cap of ₹399,603 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #83 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is GlaxoSmithKline Pharmaceuticals' Market Cap too high?
GlaxoSmithKline Pharmaceuticals' current Market Cap is ₹399,603 Mil. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #83 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #83 out of 1020 companies for Market Cap. This places GlaxoSmithKline Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 204.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Market Cap is ₹399,603 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,610.20, compared to a current price of ₹2,354.80 — trading 9.8% below its estimated fair value. The current Market Cap is ₹399,603 Mil. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Market Cap is ₹399,603 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,354.80 is trading 9.8% below its estimated GF Value™ of ₹2,610.20.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:GLAXO:
Market Cap: ₹399,603 Mil
GF Value™: ₹2,610.20 vs. price of ₹2,354.80 (9.8% below fair value)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
